Quantcast
Home > Quotes > CELG
CELG

Celgene Corporation Common Stock (CELG) Quote & Summary Data

$68.2
*  
1.54
2.21%
Get CELG Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading CELG now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
107
Today's High / Low
$ 69.33 / $ 68.13
Share Volume
5,387,563
50 Day Avg. Daily Volume
6,455,938
Previous Close
$ 69.74
52 Week High / Low
$ 110.20 / $ 66.62
Market Cap
47,688,975,488
P/E Ratio
17.35
Forward P/E (1y)
9.36
Earnings Per Share (EPS)
$ 3.93
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.87

Intraday Chart

News for CELG

Shares Traded

Share Volume:
5,387,563
50 Day Avg. Daily Volume:
6,455,938

P/E Ratio

P/E Ratio:
17.35
Forward P/E (1y):
9.36
Earnings Per Share (EPS):
$ 3.93

Trading Range

The current last sale of $68.20 is 2.37% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 69.33 $ 110.20
 Low: $ 68.13 $ 66.62

ETFs with CELG as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
6.59% iShares Nasdaq Biotechnology Index Fund (IBB) -14.30 (-12.10%)
4.09% ARK Genomic Revolution Multi-Sector ETF (ARKG) -3.03 (-9.79%)
0.82% Madrona Domestic ETF (FWDD) -5.43 (-10.16%)
0% Proshares UltraPro Nasdaq Biotechnology (UBIO) -15.69 (-38.17%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Celgene Corporation, together with its subsidiaries (collectively "we," "our," "us," "Celgene" or the "Company"), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Celgene Corporation was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID®, POMALYST®/IMNOVID®, OTEZLA®, ABRAXANE®, VIDAZA®, azacitidine for injection (generic version of VIDAZA®), THALOMID® (sold as THALOMID® or Thalidomide Celgene® outside of the U.S.) and IDHIFA®. IDHIFA® was approved by the U.S.  ... More ...  


Risk Grade

Where does CELG fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 68.91
Open Date:
Dec. 14, 2018
Close Price:
$ 68.20
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info